{
 "cells": [
  {
   "cell_type": "raw",
   "id": "9b21632e",
   "metadata": {
    "vscode": {
     "languageId": "raw"
    }
   },
   "source": [
    "---\n",
    "title: \"Development and implementation of a Primary Cell Culture with Nanostring and alphaLISA readouts to support lead optimization for sickle cell disease\"\n",
    "subtitle: \"\"\n",
    "author: \"Christopher Olsen\"\n",
    "format:\n",
    "  revealjs:\n",
    "    theme: merck-theme.scss\n",
    "    slide-number: true\n",
    "    transition: slide\n",
    "    width: 100%\n",
    "---"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8e158462",
   "metadata": {},
   "source": [
    "## Overview & Objectives\n",
    "\n",
    ":::: {.columns}\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"merck-blue-box\">\n",
    "\n",
    "**Project Context**\n",
    "\n",
    "- Sickle cell disease (SCD) affects millions globally\n",
    "- Critical need for novel therapeutics targeting fetal hemoglobin (HbF) induction\n",
    "- Challenge: Develop physiologically relevant assay system\n",
    "\n",
    "</div>\n",
    "\n",
    "<div class=\"feature-card\" style=\"margin-top: 1em;\">\n",
    "\n",
    "**Key Innovation**\n",
    "\n",
    "Primary human erythroid progenitor culture with dual readout capabilities for lead optimization\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"status-card\">\n",
    "\n",
    "**Presentation Objectives**\n",
    "\n",
    "1. Describe assay development rationale\n",
    "2. Present technical implementation strategy\n",
    "3. Demonstrate assay validation & performance\n",
    "4. Share impact on lead optimization campaigns\n",
    "5. Discuss translational insights\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::::\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "470db0c9",
   "metadata": {},
   "source": [
    "## Sickle Cell Disease: Unmet Medical Need\n",
    "\n",
    ":::: {.columns}\n",
    "\n",
    "::: {.column width=\"60%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Disease Background**\n",
    "\n",
    "- Single nucleotide mutation in β-globin gene (HBB)\n",
    "- Polymerization of deoxygenated sickle hemoglobin (HbS)\n",
    "- Vaso-occlusive crises, chronic hemolysis, organ damage\n",
    "- ~100,000 patients in US; millions worldwide\n",
    "\n",
    "</div>\n",
    "\n",
    "<div class=\"highlight-box\" style=\"margin-top: 1em;\">\n",
    "\n",
    "**Therapeutic Hypothesis**\n",
    "\n",
    "Induction of fetal hemoglobin (HbF/γ-globin) prevents HbS polymerization and ameliorates disease phenotype\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"40%\"}\n",
    "<div class=\"status-card\">\n",
    "\n",
    "**Current Therapies**\n",
    "\n",
    "- Hydroxyurea (HbF inducer)\n",
    "- Voxelotor (anti-sickling)\n",
    "- Crizanlizumab (anti-adhesion)\n",
    "- Gene therapies (recent approvals)\n",
    "\n",
    "**Opportunity:** Small molecule HbF inducers with improved efficacy and safety profiles\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::::\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b15e4cd1",
   "metadata": {},
   "source": [
    "## Assay Strategy & Design Rationale\n",
    "\n",
    "<div class=\"merck-blue-box\" style=\"margin-bottom: 1em;\">\n",
    "\n",
    "**Primary Cell Culture Model Selection**\n",
    "\n",
    "</div>\n",
    "\n",
    ":::: {.columns}\n",
    "\n",
    "::: {.column width=\"33%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Why Primary Cells?**\n",
    "\n",
    "- Physiologically relevant\n",
    "- Native chromatin context\n",
    "- Patient-derived material\n",
    "- Donor variability insights\n",
    "- Translational relevance\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"33%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Dual Readout Approach**\n",
    "\n",
    "**Nanostring nCounter**\n",
    "- Direct mRNA quantification\n",
    "- Multiplex gene expression\n",
    "- No amplification bias\n",
    "\n",
    "**alphaLISA**\n",
    "- Protein-level validation\n",
    "- High-throughput compatible\n",
    "- Quantitative HbF measurement\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"33%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Assay Requirements**\n",
    "\n",
    "- Screening throughput capability\n",
    "- Robust Z' factor (>0.5)\n",
    "- Dose-response characterization\n",
    "- Compatible with automation\n",
    "- 7-14 day culture timeline\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::::\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "82fbe256",
   "metadata": {},
   "source": [
    "## Primary Erythroid Culture Development\n",
    "\n",
    ":::: {.columns}\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"status-card\">\n",
    "\n",
    "**Culture Protocol Optimization**\n",
    "\n",
    "**Phase 1: Expansion (Days 0-7)**\n",
    "- CD34+ cell isolation from mobilized peripheral blood\n",
    "- Cytokine cocktail: SCF, IL-3, EPO\n",
    "- Cell density optimization\n",
    "- Media formulation testing\n",
    "\n",
    "**Phase 2: Differentiation (Days 7-14)**\n",
    "- Erythroid commitment\n",
    "- Hemoglobin synthesis\n",
    "- Terminal differentiation markers\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Key Optimizations**\n",
    "\n",
    "- **Donor Selection:** 3-5 SCD donors qualified\n",
    "- **Seeding Density:** 5×10⁴ cells/mL optimal\n",
    "- **Compound Addition:** Day 7 timing critical\n",
    "- **Culture Vessel:** 96-well deep well plates\n",
    "- **Incubation Time:** 7-day post-compound treatment\n",
    "\n",
    "</div>\n",
    "\n",
    "<div class=\"highlight-box\" style=\"margin-top: 1em;\">\n",
    "\n",
    "**Quality Control Metrics**\n",
    "\n",
    "Cell viability >80% | Enucleation rate | CD71/CD235a expression profile\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::::\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bbabd1fe",
   "metadata": {},
   "source": [
    "## Nanostring nCounter Implementation\n",
    "\n",
    ":::: {.columns}\n",
    "\n",
    "::: {.column width=\"55%\"}\n",
    "<div class=\"merck-blue-box\">\n",
    "\n",
    "**Technology Overview**\n",
    "\n",
    "Digital molecular barcoding for direct mRNA quantification without amplification\n",
    "\n",
    "</div>\n",
    "\n",
    "<div class=\"feature-card\" style=\"margin-top: 1em;\">\n",
    "\n",
    "**Custom CodeSet Design**\n",
    "\n",
    "- **Target Genes:** HBG1, HBG2 (γ-globin), HBB, HBA1/2\n",
    "- **Hemoglobin Switching:** BCL11A, KLF1, MYB, SOX6\n",
    "- **Erythroid Markers:** GATA1, TAL1, EPOR\n",
    "- **Housekeeping:** GAPDH, ACTB, HPRT1\n",
    "- **Total:** 15-20 genes per panel\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"45%\"}\n",
    "<div class=\"status-card\">\n",
    "\n",
    "**Workflow Implementation**\n",
    "\n",
    "1. Cell lysis & mRNA isolation\n",
    "2. Hybridization with probe sets (16-18 hrs)\n",
    "3. Nanostring nCounter detection\n",
    "4. Digital counting & normalization\n",
    "5. Data analysis pipeline\n",
    "\n",
    "**Throughput:** 12-24 samples per run\n",
    "\n",
    "**Turnaround:** 48 hours\n",
    "\n",
    "</div>\n",
    "\n",
    "<div class=\"highlight-box\" style=\"margin-top: 1em;\">\n",
    "\n",
    "**Key Advantage:** Minimal sample input (100 ng RNA)\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::::\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "82970eb4",
   "metadata": {},
   "source": [
    "## Assay Validation: Tool Compounds\n",
    "\n",
    ":::: {.columns}\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"merck-blue-box\">\n",
    "\n",
    "**Positive Controls**\n",
    "\n",
    "</div>\n",
    "\n",
    "<div class=\"feature-card\" style=\"margin-top: 1em;\">\n",
    "\n",
    "**Pomalidomide**\n",
    "- Cereblon modulator\n",
    "- Known HbF inducer\n",
    "- EC₅₀: ~50-100 nM (Nanostring)\n",
    "- Robust dose-response\n",
    "\n",
    "**Hydroxyurea**\n",
    "- Clinical standard\n",
    "- Moderate HbF induction\n",
    "- Higher concentrations required\n",
    "- Benchmark comparator\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"status-card\">\n",
    "\n",
    "**Validation Results**\n",
    "\n",
    "**mRNA-Protein Correlation:**\n",
    "- R² = 0.87 between HBG expression and HbF protein\n",
    "- Dose-response concordance across platforms\n",
    "\n",
    "**Reproducibility:**\n",
    "- Inter-assay CV: 12-18%\n",
    "- Intra-assay CV: 8-12%\n",
    "- Donor-to-donor variability managed\n",
    "\n",
    "**Selectivity:**\n",
    "- No effect on HBB expression at active concentrations\n",
    "- Erythroid differentiation maintained\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::::\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9e846af2",
   "metadata": {},
   "source": [
    "## Integration into Lead Optimization Workflow\n",
    "\n",
    ":::: {.columns}\n",
    "\n",
    "::: {.column width=\"40%\"}\n",
    "<div class=\"status-card\">\n",
    "\n",
    "**Screening Cascade**\n",
    "\n",
    "1. **Primary Screen**\n",
    "   - alphaLISA (HbF protein)\n",
    "   - Single concentration or dose-response\n",
    "   - Throughput: ~500 compounds/month\n",
    "\n",
    "2. **Secondary Confirmation**\n",
    "   - Nanostring gene panel\n",
    "   - Mechanism insights\n",
    "   - Multiple donors\n",
    "\n",
    "3. **Profiling**\n",
    "   - Full gene expression analysis\n",
    "   - Off-target assessment\n",
    "   - Cytotoxicity counter-screen\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"60%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Decision-Making Impact**\n",
    "\n",
    "**SAR Development:**\n",
    "- Identified 3 chemical series with EC₅₀ <100 nM\n",
    "- Guided optimization of potency and selectivity\n",
    "- Eliminated compounds with erythroid toxicity\n",
    "\n",
    "**Mechanistic Insights:**\n",
    "- BCL11A downregulation pathway confirmed\n",
    "- Novel KLF1-independent inducers discovered\n",
    "- Chromatin modifier class characterized\n",
    "\n",
    "**Translational Path:**\n",
    "- Primary cell data informed candidate selection\n",
    "- Donor variability predicted clinical heterogeneity\n",
    "- De-risked progression decisions\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::::\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "32360379",
   "metadata": {},
   "source": [
    "## Challenges & Solutions\n",
    "\n",
    ":::: {.columns}\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Technical Challenges**\n",
    "\n",
    "**1. Donor Variability**\n",
    "- **Issue:** 3-5 fold baseline HbF differences\n",
    "- **Solution:** Normalized fold-change metrics; qualified donor panel\n",
    "\n",
    "**2. Culture Reproducibility**\n",
    "- **Issue:** Batch-to-batch media variation\n",
    "- **Solution:** Lot testing; controlled serum batches\n",
    "\n",
    "**3. Throughput Limitations**\n",
    "- **Issue:** Manual culture steps\n",
    "- **Solution:** Semi-automation with Hamilton; batch processing\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Analytical Challenges**\n",
    "\n",
    "**4. Nanostring Sample Throughput**\n",
    "- **Issue:** 12-24 samples/run limitation\n",
    "- **Solution:** Prioritized compounds; alphaLISA primary screen\n",
    "\n",
    "**5. Data Integration**\n",
    "- **Issue:** Correlating mRNA and protein data\n",
    "- **Solution:** Custom analysis pipeline; unified database\n",
    "\n",
    "**6. Assay Interference**\n",
    "- **Issue:** Autofluorescence from compounds\n",
    "- **Solution:** AlphaLISA format immune to interference\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::::\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "73c1e521",
   "metadata": {},
   "source": [
    "## Key Takeaways & Impact\n",
    "\n",
    "<div class=\"merck-blue-box\" style=\"margin-bottom: 1em;\">\n",
    "\n",
    "**Primary Accomplishments**\n",
    "\n",
    "</div>\n",
    "\n",
    ":::: {.columns}\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Assay Development**\n",
    "\n",
    "✓ Established robust primary cell culture system (Z' >0.7)\n",
    "\n",
    "✓ Implemented dual-readout platform (Nanostring + alphaLISA)\n",
    "\n",
    "✓ Validated with clinical and tool compounds\n",
    "\n",
    "✓ Achieved screening throughput capability\n",
    "\n",
    "✓ Generated mechanistic insight framework\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Drug Discovery Impact**\n",
    "\n",
    "✓ Supported 3 lead optimization campaigns\n",
    "\n",
    "✓ Screened >2,500 compounds over 18 months\n",
    "\n",
    "✓ Identified novel chemical series with <100 nM potency\n",
    "\n",
    "✓ Enabled mechanism-based compound classification\n",
    "\n",
    "✓ Informed candidate selection for in vivo studies\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::::\n",
    "\n",
    "<div class=\"status-card\" style=\"margin-top: 1em;\">\n",
    "\n",
    "**Scientific Contribution:** Physiologically relevant, translational assay bridging medicinal chemistry and clinical development for sickle cell disease therapeutics\n",
    "\n",
    "</div>\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0f1cdd09",
   "metadata": {},
   "source": [
    "## Acknowledgments\n",
    "\n",
    ":::: {.columns}\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Collaborators & Contributors**\n",
    "\n",
    "**Biology Team:**\n",
    "- Primary cell culture development\n",
    "- Assay validation & execution\n",
    "- Data analysis & interpretation\n",
    "\n",
    "**Chemistry Team:**\n",
    "- Compound synthesis & SAR\n",
    "- Lead optimization campaigns\n",
    "\n",
    "**Translational Sciences:**\n",
    "- Clinical sample coordination\n",
    "- Biomarker strategy\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::: {.column width=\"50%\"}\n",
    "<div class=\"feature-card\">\n",
    "\n",
    "**Technical Support**\n",
    "\n",
    "**Core Facilities:**\n",
    "- Nanostring nCounter operations\n",
    "- Flow cytometry core\n",
    "- Automation support\n",
    "\n",
    "**External Partners:**\n",
    "- SCD patient advocacy groups\n",
    "- Clinical material suppliers\n",
    "- Technology vendors\n",
    "\n",
    "</div>\n",
    ":::\n",
    "\n",
    "::::\n",
    "\n",
    "<div class=\"highlight-box\" style=\"margin-top: 1em; text-align: center; font-size: 1.2em;\">\n",
    "\n",
    "**Questions?**\n",
    "\n",
    "</div>\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ac09a27b",
   "metadata": {},
   "source": [
    "## Backup Slides\n",
    "\n",
    "<div class=\"merck-blue-box\" style=\"text-align: center; padding: 2em; font-size: 1.5em;\">\n",
    "\n",
    "**Supplementary Data & Technical Details**\n",
    "\n",
    "</div>\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
